Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2017
Event: Announcement of results of operations for the second quarter of 2017.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced and directs readers to Exhibit 99.1 (the press release) for detailed figures.
The filing notes the use of non-GAAP financial measures, specifically "net earnings from continuing operations excluding specified items," to provide visibility on ongoing business performance.
Material Changes and Adjustments
The filing outlines specific items excluded from non-GAAP measures to adjust for unusual or unpredictable factors. These include:
- Expenses primarily associated with acquisitions and restructuring actions.
- Charges related to cost reduction initiatives.
- A gain on the sale of the Medical Optics business.
- Venezuela devaluation expenses.
- Resolution of various tax positions from prior years.
- Intangible amortization expense.
Guidance, Outlook, and Management Commentary
Management states that non-GAAP measures are used internally to monitor business performance and are presented to help investors evaluate ongoing operations. However, the company cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures. No specific forward-looking guidance or outlook figures are contained within this 8-K text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 20, 2017) for specific Q2 2017 revenue and earnings figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings to understand the impact of the Medical Optics sale and Venezuela devaluation.
- Assess the magnitude of restructuring and acquisition-related expenses excluded from non-GAAP results.
- Confirm the treatment of intangible amortization in management's internal performance assessment.